Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 10/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 8/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CSNK1A1L | Q8N752 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.35 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394801 | 1.00 | CSNK1E (0.54) | CSNK1EMAPK14CSNK1DMAPK11EGFR | |
| SCHEMBL1394662 | 0.91 | CSNK1E (0.67) | CSNK1EMAPK14CSNK1DMAPK11EGFR | |
| SCHEMBL1394720 | 0.91 | CSNK1E (0.67) | CSNK1EMAPK14CSNK1DMAPK11EGFR | |
| SCHEMBL1395184 | 0.89 | MAPK14 (0.49) | CSNK1EMAPK14CSNK1DMAPK11EGFR | |
| SCHEMBL1395186 | 0.89 | MAPK14 (0.49) | CSNK1EMAPK14CSNK1DMAPK11EGFR | |
| SCHEMBL1394527 | 0.85 | CSNK1E (0.40) | CSNK1EAURKAAURKBINCENPTPX2 | |
| SCHEMBL1394530 | 0.85 | CSNK1E (0.40) | CSNK1EAURKAAURKBINCENPTPX2 | |
| SCHEMBL1394200 | 0.84 | MAPK14 (0.47) | CSNK1EMAPK14CSNK1DMAPK11EGFR | |
| SCHEMBL1394120 | 0.84 | MAPK14 (0.44) | CSNK1EMAPK14CSNK1DMAPK11EGFR | |
| SCHEMBL1394119 | 0.84 | MAPK14 (0.44) | CSNK1EMAPK14CSNK1DMAPK11EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370446-B1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES,PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-11-25 | — | — | EP | claimed |
| US-8546395-B2 | 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | claimed |
| US-20120010208-A1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | US | claimed |
| EP-2370446-B1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES,PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-11-25 | — | — | EP | disclosed |
| US-8546395-B2 | 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120010208-A1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010208-A1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, CBR1, CNR1 | CSNK1E 2042/4885MAPK14 4289/4885CSNK1D 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.